Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00050284 · ClinicalTrials.gov registry record
Discontinuation of Antiretroviral Therapy in Patients With Asymptomatic HIV Infection
A clinical trial, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- Completed
- Registry status
- 158
- Enrollment target
NCT00050284: Completed study, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
NCT00050284 is a clinical trial that has completed, run by National Institute of Allergy and Infectious Diseases (NIAID). The registered enrollment target is 158 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00050284 has completed, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- COMPLETED
- Registry status
- 158 participants
- Enrollment target
Study Summary
The purpose of this study is to determine whether patients who have asymptomatic HIV infection can discontinue antiretroviral therapy (ART) without adverse clinical, virologic, or immunologic consequences. This study will also assess the virologic, immunologic, and clinical outcomes in any patients who restart ART.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 158 participants |
What the finished NCT00050284 record still lists
NCT00050284 is an observational study that tracks outcomes without assigning an intervention. The registered 158 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 0 interventions.
NCT00050284 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00050284 about?
NCT00050284 is a clinical study titled "Discontinuation of Antiretroviral Therapy in Patients With Asymptomatic HIV Infection". The purpose of this study is to determine whether patients who have asymptomatic HIV infection can discontinue antiretroviral therapy (ART) without adverse clinical, virologic, or immunologic consequences. This study will also assess the virologic, immunologic, and clinical outcomes in any patients ...
What is the current status of trial NCT00050284?
This trial is currently completed. The enrollment target is 158 participants.
Who is sponsoring clinical trial NCT00050284?
This trial is sponsored by National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04486833 · 158 participants · Phase 1
Quaratusugene Ozeplasmid (Reqorsa) and Osimertinib in Patients With Advanced Lung Cancer Who Progressed on Osimertinib
- NCT04697966 · 158 participants · NA
Mechanisms and Predictors of Change in App-Based Mindfulness Training for Adolescents
- NCT04969835 · 158 participants · Phase 1
A Study Evaluating the Safety, Pharmacokinetics and Early Efficacy of AVA6000 in Solid Tumours
- NCT05230732 · 158 participants · NA
Neuromodulation of Inflammation and Endothelial Function